Infection Control Programme, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Swiss Med Wkly. 2019 Jul 24;149:w20110. doi: 10.4414/smw.2019.20110. eCollection 2019 Jul 15.
OBJECTIVES: Most urinary tract infections (UTIs) are treated empirically with antibiotics, making comprehensive resistance surveillance data essential to guide empiric regimens. We describe trends in the antibiotic resistance of urinary Enterobacteriaceae isolates in Switzerland between 2009 and 2016.
We analysed data from routinely collected Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis urinary samples from community and hospital settings in Switzerland. The data were collected by ANRESIS, the national laboratory-based antimicrobial resistance surveillance system. Our analyses focused on resistance to antibiotics commonly prescribed for UTIs for the period 2009–2016. Only the first isolate per patient per year was included.
297,200 urinary samples were included in the analysis, of which 246,656 (83.0%) were E. coli isolates. Overall, E. coli showed high susceptibility to 3rd/4th-generation cephalosporins, nitrofurantoin and fosfomycin, with the annual proportions of resistant isolates <6%, <5% and <2%, respectively, for all study years. Resistance to fluoroquinolones was >14% and increased over time (from 14.5% in 2009 to 19.3% in 2016). Resistance to cotrimoxazole was >20% for the whole study period. K. pneumoniae (n = 32,757; 11.0%) showed low resistance to cotrimoxazole and quinolones (<11% and <12%, respectively), while for P. mirabilis (n = 17,787; 6.0%) the proportion of resistant isolates was <35% for cotrimoxazole and <18% for quinolones. Even though quinolone resistance remained low for both pathogens (<12% for K. pneumoniae and <18% for P. mirabilis), it increased significantly over time. Proportions of isolates resistant to 3rd/4th generation cephalosporins remained low (<5% for K. pneumoniae and <2% for P. mirabilis), but in the case of K. pneumoniae they increased over time.
Swiss surveillance data confirm that resistance among uropathogenic E. coli isolates to nitrofurantoin and fosfomycin remains low. While resistance to 3rd/4th-generation cephalosporins also remains relatively low, it has been increasing and needs further surveillance. As for K. pneumoniae and P. mirabilis, high levels of susceptibility to 3rd-generation cephalosporins and quinolones were confirmed, while high prevalences of resistance to nitrofurantoin and fosfomycin discourage their use as first-line therapies for these pathogens.  .
目的:大多数尿路感染(UTI)采用抗生素经验性治疗,因此全面的耐药监测数据对于指导经验性治疗方案至关重要。我们描述了 2009 年至 2016 年期间瑞士尿肠杆菌分离株抗生素耐药性的趋势。 方法:我们分析了瑞士社区和医院环境中常规收集的大肠埃希菌、肺炎克雷伯菌和奇异变形杆菌尿样的数据。这些数据由国家基于实验室的抗菌药物耐药性监测系统 ANRESIS 收集。我们的分析重点是 2009-2016 年期间常用于治疗 UTI 的抗生素的耐药性。每年每位患者仅包括第一个分离株。 结果:共纳入 297200 例尿样进行分析,其中 246656 例(83.0%)为大肠埃希菌分离株。总体而言,大肠埃希菌对第三代/第四代头孢菌素、呋喃妥因和磷霉素高度敏感,所有研究年份的耐药分离株比例均<6%、<5%和<2%。氟喹诺酮类药物的耐药率>14%,且呈上升趋势(2009 年为 14.5%,2016 年为 19.3%)。复方磺胺甲噁唑的耐药率>20%,整个研究期间均如此。肺炎克雷伯菌(n=32757;11.0%)对复方磺胺甲噁唑和喹诺酮类药物的耐药率较低(分别为<11%和<12%),而奇异变形杆菌(n=17787;6.0%)对复方磺胺甲噁唑和喹诺酮类药物的耐药分离株比例均<35%和<18%。尽管两种病原体的喹诺酮类药物耐药率仍然较低(肺炎克雷伯菌<12%,奇异变形杆菌<18%),但耐药率呈显著上升趋势。对第三代/第四代头孢菌素的耐药分离株比例仍然较低(肺炎克雷伯菌<5%,奇异变形杆菌<2%),但在肺炎克雷伯菌中呈上升趋势。 结论:瑞士监测数据证实,尿肠杆菌分离株对呋喃妥因和磷霉素的耐药率仍然较低。虽然第三代/第四代头孢菌素的耐药率也相对较低,但耐药率一直在上升,需要进一步监测。对于肺炎克雷伯菌和奇异变形杆菌,确认了对第三代头孢菌素和喹诺酮类药物的高度敏感性,而对呋喃妥因和磷霉素的高耐药率不鼓励将其作为这些病原体的一线治疗药物。